Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.
Earnings & Valuation
This table compares Anteris Technologies Global and NeurAxis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $1.91 million | 306.41 | -$94.14 million | ($1.95) | -3.08 |
| NeurAxis | $5.32 million | 14.58 | -$14.63 million | ($0.78) | -7.91 |
NeurAxis has higher revenue and earnings than Anteris Technologies Global. NeurAxis is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Anteris Technologies Global and NeurAxis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -4,619.27% | -77.69% | -67.99% |
| NeurAxis | -492.76% | N/A | -641.25% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Anteris Technologies Global and NeurAxis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 1 | 3 | 0 | 2.40 |
| NeurAxis | 0 | 1 | 1 | 0 | 2.50 |
Anteris Technologies Global presently has a consensus target price of $14.00, indicating a potential upside of 133.14%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 110.70%. Given Anteris Technologies Global’s higher probable upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than NeurAxis.
Institutional and Insider Ownership
11.8% of NeurAxis shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Anteris Technologies Global has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Summary
NeurAxis beats Anteris Technologies Global on 8 of the 14 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.
About NeurAxis
NeurAxis, Inc. (NASDAQ: NRXS) is a medical technology company focused on developing and commercializing non-invasive neuromodulation therapies for functional gastrointestinal and other nervous-system-related disorders. The company’s approach is designed to influence neural signaling through targeted electrical stimulation. NeurAxis’s principal product is IB-Stim, a prescription, percutaneous electrical nerve-field stimulation device intended for use in adolescents with functional abdominal pain associated with irritable bowel syndrome and related functional gastrointestinal disorders.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
